Blood Plasma Derivatives Global Market Report 2024

The blood plasma derivatives market size has grown strongly in recent years. It will grow from $48.26 billion in 2023 to $52.61 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth observed during the historical period can be attributed to several factors, including the increased prevalence of hemophilia and bleeding disorders, a growing geriatric population, heightened awareness and improved diagnostic capabilities, an increase in surgical procedures, and the expansion of global blood transfusion services. These factors collectively contributed to the demand for blood plasma derivatives, as they play a critical role in treating various medical conditions, especially those related to coagulation and bleeding disorders.

The blood plasma derivatives market size is expected to see strong growth in the next few years. It will grow to $75 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to several key factors, including the emergence of therapies for rare diseases, the increasing prevalence of chronic diseases, a rise in healthcare expenditure, the adoption of patient-centric treatment approaches, and the continuous growth of healthcare infrastructure. Major trends expected in the forecast period include advancements in fractionation technologies, a focus on patient-centric approaches, increased collaborations and partnerships within the industry, expanding applications in neurology-related conditions, and ongoing technological innovations in plasma fractionation. These trends reflect the industry's commitment to addressing evolving healthcare needs through improved technologies, patient-focused care, and strategic collaborations.

The escalation in the prevalence of immunodeficiency disorders is anticipated to be a primary driver behind the growth trajectory of the blood plasma derivatives market. Immunodeficiency disorders encompass illnesses that compromise either wholly or partially the body's immune system functionality. Within the spectrum of medical treatments, blood plasma derivatives play a crucial role, particularly in addressing various medical conditions, including immune deficiency disorders. Plasma, comprising proteins and salts, hosts a diverse array of over 100 different proteins, with immunoglobulins being notably utilized in managing primary immunodeficiencies. The occurrence of immunodeficiency disorders can be linked to poor nutrition or malnutrition, resulting in deficiencies in macro- and micronutrients. For instance, a report shared by the World Health Organization (WHO) in July 2022 revealed that globally, 828 million individuals were affected by hunger in 2021, with hunger being a significant contributor to malnutrition. Hence, the increasing prevalence of immune deficiency disorders serves as a significant impetus propelling the expansion of the blood plasma derivatives market.

The surge in trauma and accident cases stands as a pivotal factor driving the anticipated growth of the blood plasma derivatives market in the foreseeable future. Trauma and accident cases pertain to situations wherein individuals sustain physical injuries or harm due to unforeseen incidents or events. Blood plasma derivatives are instrumental in such scenarios, utilized for various purposes such as replacing clotting factors, managing hemorrhagic shock, regulating hemostasis and coagulation, facilitating fluid replacement, aiding wound healing, and addressing edema while supporting fluid balance. For example, in December 2022, statistics provided by the Ministry of Road Transport and Highways in India reported 4,12,432 accidents in 2021. Moreover, a report published by the National Highway Traffic Safety Administration in the US stated that 42,915 individuals lost their lives in motor vehicle traffic crashes in 2021. Hence, the upsurge in trauma and accident cases significantly contributes to driving the growth trajectory of the blood plasma derivatives market.

The projected increase in the prevalence of hemophilia is set to be a significant driver propelling the growth of the blood plasma derivatives market. Hemophilia, a hereditary bleeding disorder, hinders proper blood clotting, leading to both spontaneous bleeding and bleeding following injury or surgical procedures. Individuals experiencing hemostasis-related issues, whether hereditary or acquired, often benefit from blood plasma-derived products or medications to effectively manage hemostasis. Treatments for conditions such as hemophilia A, von Willebrand disease, and hemophilia B involve the use of factor VIII, factor VIII/vWF, and factor IX concentrates, respectively. Notably, statistics from the Centers for Disease Control and Prevention (CDC) in August 2022 reported 3.7 cases of hemophilia B and 12 cases of hemophilia A per 100,000 American males in the United States, with 1 in 5,617 male births affected by hemophilia B and 1 in 19,283 male births affected by hemophilia A. Thus, the escalating prevalence of hemophilia serves as a driving force behind the expansion of the blood plasma derivatives market.

Prominent entities within the blood plasma derivatives market are strategically engaging in partnerships to gain a competitive advantage. These strategic alliances aim to ensure patients in need have consistent access to crucial plasma-derived medications, addressing the growing demand for immunoglobulins in France and beyond. A noteworthy example occurred in January 2022 when Kedrion S.p.A., an Italy-based biopharmaceutical company specializing in plasma-derived therapies, collaborated with LPB, a UK-based pharmaceutical company specializing in biological medicinal products. Under this partnership, Kedrion will utilize plasma acquired in France by the Etablissement Français du Sang (EFS) to manufacture immunoglobulins in Hungary. These immunoglobulins will supplement the current supply available to hospitals nationwide, complying with and operating under the supervision of French health authorities. This import from LFB in France will contribute to reinforcing the supply chain of crucial immunoglobulins, aiding in meeting the healthcare demands of patients.

In April 2022, Grifols S.A., a Spain-based leader in the production of plasma-derived medicines, successfully acquired Biotest AG for an undisclosed amount. This strategic acquisition positions Grifols to enhance the accessibility of plasma medicines for patients, accelerate and broaden its product portfolio, take ownership of the most extensive private European network of plasma facilities boasting 87 locations, and contribute to revenue growth and profitability expansion. Biotest AG, based in Germany, is recognized for its role as a producer of various human blood plasma-derived concentrates used in intensive care medicines.

Major companies operating in the blood plasma derivatives market report are Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Monobind Inc., Intas Pharmaceuticals Ltd., Octapharma Plasma, Fusion Pharmaceuticals Inc.

North America was the largest region in the blood plasma derivatives market in 2023. The regions covered in the blood plasma derivatives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood plasma derivatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of blood plasma derivatives include albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Albumin is a key protein present in these derivatives, contributing to the regulation of osmotic pressure in the blood and aiding in the transportation of hormones, metals, and other molecules throughout the body. These derivatives find application in various medical conditions such as hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's disease, and more. They are utilized by diverse end-users, including hospitals, clinics, and other healthcare institutions.

The blood plasma derivatives market research report is one of a series of new reports that provides blood plasma derivatives market statistics, including blood plasma derivatives industry global market size, regional shares, competitors with a blood plasma derivatives market share, detailed blood plasma derivatives market segments, market trends and opportunities, and any further data you may need to thrive in the blood plasma derivatives industry. This blood plasma derivatives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood plasma derivatives market consists of sales of fibrinogen, globulin, sodium, potassium, bicarbonate, and chloride. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.